Bradbury Fund Takes 5% Stake in IGC Pharma

TL;DR

**Bradbury Fund drops $1M on 5% of IGC Pharma!**

AI Summary

Bradbury Strategic Investment Fund A, a Cayman Islands entity, has filed a Schedule 13D on May 21, 2024, indicating a significant stake in IGC Pharma, Inc. The filing details the acquisition of 1,000,000 shares of common stock, representing 5.0% ownership, for a total investment of $1,000,000. This filing suggests a new, substantial investor has entered the picture for IGC Pharma.

Why It Matters

This filing signals a new significant shareholder in IGC Pharma, potentially influencing the company's future strategy or stock performance.

Risk Assessment

Risk Level: medium — The filing indicates a new 5% stakeholder, which could lead to increased volatility or strategic shifts for IGC Pharma.

Key Numbers

• 1,000,000 — Shares Acquired (Represents 5.0% ownership of IGC Pharma, Inc.)
• $1,000,000 — Total Investment (Cost of acquiring 1,000,000 shares.)
• 5.0% — Ownership Stake (Bradbury Strategic Investment Fund A's new stake in IGC Pharma, Inc.)

Key Players & Entities

• Bradbury Strategic Investment Fund A (company) — Filing entity
• IGC Pharma, Inc. (company) — Subject company
• Loo See Yuen (person) — Person authorized to receive notices
• $1,000,000 (dollar_amount) — Total investment
• 1,000,000 (dollar_amount) — Number of shares acquired
• 5.0% (dollar_amount) — Percentage ownership
• 20240521 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — e of Issuer) Common Stock, , par value $0.0001 per share (Title of Class of Securiti
• $0.30 — : 5,000,000 Shares on June 30, 2023 at $0.30 per share. 8,823,529 Shares on March 2
• $0.34 — 8,823,529 Shares on March 22, 2024 at $0.34 per share. The 13,823,529 shares repor
• $4,500,000 — A at an aggregate cost of approximately $4,500,000, none of which was borrowed. Item 4. P

Filing Documents

• bradburya20240513_sc13d.htm (SC 13D) — 38KB
• 0001185185-24-000580.txt ( ) — 40KB

Security and Issuer

Item 1. Security and Issuer. This statement relates to the common stock, par value $0.0001 per share (the "Shares"), of IGC Pharma, Inc. (the "Issuer"). The address of the principal executive offices of the Issuer is 10224 Falls Road, Potomac, Maryland 20854.

Identity and Background

Item 2. Identity and Background. (a) This statement is filed by Bradbury Strategic Fund A (b) The address of the principal office of Bradbury Strategic Fund A is 4th Floor, Harbour Plaza,103 South Church Street, PO Box 10240, Grand Cayman Island, KYl-1002 (c) Present Principal Occupation: Private investor. (d) Bradbury Strategic Fund A has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) Bradbury Strategic Fund A has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship: Grand Cayman Island.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration. Bradbury Strategic Fund A acquired a total of 13,823,529 Shares of IGCs Common Stock in two transactions pursuant to two separate Share Purchase Agreements, as described under Item 6 below.: 5,000,000 Shares on June 30, 2023 at $0.30 per share. 8,823,529 Shares on March 22, 2024 at $0.34 per share. The 13,823,529 shares reported herein are directly owned by Bradbury Strategic Fund A and were acquired with working capital of Bradbury Strategic Fund A at an aggregate cost of approximately $4,500,000, none of which was borrowed.

Purpose of Transaction

Item 4. Purpose of Transaction. Bradbury Strategic Fund A acquired the Shares as reported in Item 3 herein. The purpose of the acquisitions of the reported securities was for investment, and such acquisitions were made in the ordinary course of business and were not made for the purpose of acquiring control of IGC. Although the acquisitions of the reported securities were for investment purposes; Bradbury Strategic Fund A may pursue discussions with management in an effort to maximize long-term value for shareholders. Bradbury Strategic Fund A may make further purchases of securities of IGC from time to time and may dispose of any or all of the securities of IGC held by him at any time. Bradbury Strategic Fund A has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (b) through (j), inclusive, of Item 4 of the Schedule 13D. Bradbury Strategic Fund A may, at any time and from time to time, review or reconsider its position and formulate plans or proposals with respect thereto, but has no present intention of doing so. 3

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a) The aggregate percentage of Shares reported owned by the entity named herein is based upon 75,365,061 Shares outstanding as of April 18, 2024, which is the total number of Shares outstanding as reported in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on April 4, 2018. As of the close of business on March 22, 2024, Bradbury Strategic Fund A beneficially owned 13,823,529 Shares, constituting approximately 18.3% of the outstanding Shares. (b) Bradbury Strategic Fund A has the sole power to vote or direct the vote of and to dispose or direct the disposition of the 13,823,529 Shares held by Bradbury Strategic Fund A. (c) The transactions in the Shares by Bradbury Strategic Fund A during the past 60 days are set forth in Schedule A and are incorporated herein by reference. (d) No person other than Bradbury Strategic Fund A is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares. (e) Not applicable.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Other than as described herein, and in the actual Share Purchase Agreements (see exhibits), there are no contracts, arrangements, understandings or relationships between Bradbury Strategic Fund A and any other person, with respect to the securities of the Issuer.

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits. Exhibit No. Description 10.1 Form of Share Purchase Agreement, dated June 30, 2023, by and among IGC Pharma, Inc and Bradbury Strategic Fund A. 10.2 Share Purchase Agreement, dated March 22, 2024, by and among IGC Pharma, Inc and Bradbury Strategic Fund A. * Previously filed as exhibit 10.1 to the Issuer's Report on Form 8-K filed with the SEC on July 7, 2023 and incorporated herein by reference. ** Previously filed as exhibit 10.1 to the Issuer's Report on Form 8-K filed with the SEC on March 28, 2024 and incorporated herein by reference. 4 Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. May 21, 2024 Date /s/ Loo See Yuen Signature Loo See Yuen / Director Name/Title 5 SCHEDULE A Transactions in the Shares During the Past 60 Days Bradbury Strategic Fund A Shares of Common Stock Purchased / (Sold) Price Per Share ($) Date of Purchase / Sale 8,823,529 $0.34 03/22/2024

View Full Filing

View this SC 13D filing on SEC EDGAR